Wedbush Reduces Earnings Estimates for Adherex Technologies

Key Points

• Wedbush analysts cut their FY2025 earnings estimates for Adherex Technologies to $0.32 per share, down from $0.42, while the current consensus estimate is a loss of $0.11 per share.
• Adherex Technologies reported a quarterly loss of ($0.11) per share, missing estimates and generating revenue of $9.76 million, which exceeded analyst expectations.
• Despite the downgrade, Adherex Technologies maintains a consensus rating of "Buy" from analysts, with a price target averaging $13.33 per share.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Stock analysts at Wedbush reduced their FY2025 earnings per share (EPS) estimates for shares of Adherex Technologies in a research report issued on Thursday, August 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $0.32 per share for the year, down from their previous forecast of $0.42. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Adherex Technologies' Q4 2025 earnings at $0.07 EPS and Q1 2026 earnings at $0.08 EPS.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The company had revenue of $9.76 million during the quarter, compared to analysts' expectations of $9.52 million.

Several other analysts have also recently issued reports on FENC. Zacks Research cut shares of Adherex Technologies from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday. Wall Street Zen raised shares of Adherex Technologies from a "hold" rating to a "buy" rating in a research note on Sunday, August 17th. Finally, Craig Hallum lifted their target price on shares of Adherex Technologies from $13.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $13.33.

Adherex Technologies Price Performance

Adherex Technologies stock traded up $0.49 during midday trading on Monday, reaching $8.66. The company had a trading volume of 166,030 shares, compared to its average volume of 58,881. Adherex Technologies has a 12-month low of $3.96 and a 12-month high of $9.42. The company has a market capitalization of $240.83 million, a P/E ratio of -20.62 and a beta of 0.40. The firm's fifty day simple moving average is $8.42 and its 200-day simple moving average is $7.20.

Insiders Place Their Bets

In other Adherex Technologies news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $8.09, for a total transaction of $80,900.00. Following the completion of the transaction, the director owned 55,878 shares of the company's stock, valued at $452,053.02. This trade represents a 15.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 31,119 shares of company stock worth $254,546 over the last ninety days. Company insiders own 11.76% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Adherex Technologies by 32.1% during the fourth quarter. Bank of America Corp DE now owns 35,827 shares of the company's stock worth $226,000 after buying an additional 8,703 shares during the period. Barclays PLC boosted its stake in Adherex Technologies by 13.9% during the fourth quarter. Barclays PLC now owns 35,672 shares of the company's stock worth $225,000 after buying an additional 4,353 shares during the period. BNP Paribas Financial Markets boosted its stake in Adherex Technologies by 11.5% during the fourth quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company's stock worth $282,000 after buying an additional 4,610 shares during the period. Solas Capital Management LLC boosted its stake in Adherex Technologies by 17.0% during the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock worth $14,226,000 after buying an additional 327,383 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Adherex Technologies by 31.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock worth $83,000 after buying an additional 3,155 shares during the period. Hedge funds and other institutional investors own 55.51% of the company's stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.